Target intelligence / Profile preview

Aldehyde dehydrogenase 8 family member A1 (ALDH8A1)

Target
ALDH8A1
Molecular classification
Enzyme, Oxidoreductase (specifically, aldehyde dehydrogenase family, EC 1.2.1)
01

Overview

Aldehyde dehydrogenase 8 family member A1 (ALDH8A1) is a human enzyme coded by the ALDH8A1 gene. It is classified in the aldehyde dehydrogenase superfamily, responsible for oxidizing aldehydes to their corresponding acids using NAD as a cofactor. ALDH8A1 was initially proposed to mediate the biosynthesis of 9-cis-retinoic acid, but current data indicates its main role is as the aldehyde dehydrogenase of the kynurenine pathway, converting 2-aminomuconic semialdehyde to 2-aminomuconate during tryptophan catabolism. It shows strong specificity and activity for 9-cis-retinal compared to other retinoids, and contributes to pathways important for vitamin A metabolism and neuroactive compound biosynthesis. Dysfunction of related aldehyde dehydrogenases is implicated in various metabolic and neurological disorders, but ALDH8A1-specific pathologies are less well defined[1][3][4][7][8].

Other names
ALDH8A1ALDH12DJ352A20.2aldehyde dehydrogenase 8 family, member A12-aminomuconic semialdehyde dehydrogenaseretinal dehydrogenase 4 (RALDH4)[1][3][5][6][9]
02

Mechanism of action

Not explicitly characterized for drugs; inhibitors would function by blocking oxidoreductase activity of the enzyme[3][7].

03

Biological functions

Catalyzes NAD-dependent oxidation of 2-aminomuconic semialdehyde in the kynurenine pathway of tryptophan degradationInvolved in retinoic acid biosynthesis (conversion of 9-cis-retinal to 9-cis-retinoic acid)Retinal dehydrogenase activityAldehyde dehydrogenase (NAD) activity[1][3][4][7][8]
04

Disease associations

Succinic semialdehyde dehydrogenase deficiencyOther potential roles in metabolism-linked disease (retinoic acid signaling, tryptophan/kynurenine pathway disorders)[3][7]
05

Safety considerations

Not directly established; theoretical concerns may stem from interfering with retinoic acid metabolism or the kynurenine pathway, which are important in neurodevelopment, immune function, and cellular metabolism. Inhibition could impact metabolic homeostasis.
06

Interacting drugs

There are no widely cataloged drugs or inhibitors targeting ALDH8A1 specifically in clinical use. General aldehyde dehydrogenase inhibitors may act, but no specific interactions are reported in current databases[3][7].
07

Biomarkers

No established clinical biomarkers for ALDH8A1 activity or expression in patient selection or efficacy monitoring.

Beyond the preview

Go deeper on Aldehyde dehydrogenase 8 family member A1 (ALDH8A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldehyde dehydrogenase 8 family member A1 (ALDH8A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call